.Attributes Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ state-of-the-art bosom cancer cells as well as energetic or even secure mind metastases presented constant intracranial activity as well as wide spread efficiency of T-DXd.